71 related articles for article (PubMed ID: 16103743)
21. Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial--an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002).
Fasola G; Belvedere O; Aita M; Zanin T; Follador A; Cassetti P; Meduri S; De Pangher V; Pignata G; Rosolen V; Barbone F; Grossi F
Oncologist; 2007 Oct; 12(10):1215-24. PubMed ID: 17962615
[TBL] [Abstract][Full Text] [Related]
22. [Clinicopathological characteristics and prognosis of malignant pleural mesothelioma].
Chen WH; Zhang XL; Dai HP; Tong ZH; Zhang YH; Jin ML
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Nov; 36(11):825-8. PubMed ID: 24507393
[TBL] [Abstract][Full Text] [Related]
23. [A case of triple malignancies (gastric cancer, lung cancer and malignant pleural mesothelioma) after asbestos exposure].
Kishimoto T
Nihon Kokyuki Gakkai Zasshi; 2003 Apr; 41(4):304-9. PubMed ID: 12795187
[TBL] [Abstract][Full Text] [Related]
24. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
Neragi-Miandoab S; Richards WG; Sugarbaker DJ
Int J Surg; 2008 Aug; 6(4):293-7. PubMed ID: 18585112
[TBL] [Abstract][Full Text] [Related]
25. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
Pass HI; Lott D; Lonardo F; Harbut M; Liu Z; Tang N; Carbone M; Webb C; Wali A
N Engl J Med; 2005 Oct; 353(15):1564-73. PubMed ID: 16221779
[TBL] [Abstract][Full Text] [Related]
26. Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis.
Mosleh B; Schelch K; Mohr T; Klikovits T; Wagner C; Ratzinger L; Dong Y; Sinn K; Ries A; Berger W; Grasl-Kraupp B; Hoetzenecker K; Laszlo V; Dome B; Hegedus B; Jakopovic M; Hoda MA; Grusch M
Thorac Cancer; 2023 Aug; 14(22):2177-2186. PubMed ID: 37340889
[TBL] [Abstract][Full Text] [Related]
27. Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital.
Huncharek M; Kelsey K; Mark EJ; Muscat J; Choi N; Carey R; Christiani D
Anticancer Res; 1996; 16(3A):1265-8. PubMed ID: 8702248
[TBL] [Abstract][Full Text] [Related]
28. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
Gube M; Taeger D; Weber DG; Pesch B; Brand P; Johnen G; Müller-Lux A; Gross IM; Wiethege T; Weber A; Raithel HJ; Kraus T; Brüning T
Arch Toxicol; 2011 Mar; 85(3):185-92. PubMed ID: 20737138
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors and survival in malignant pleural mesothelioma.
Van Gelder T; Damhuis RA; Hoogsteden HC
Eur Respir J; 1994 Jun; 7(6):1035-8. PubMed ID: 7925870
[TBL] [Abstract][Full Text] [Related]
31. [Clinico-pathological prognostic factors in malignant pleural mesothelioma].
Nakano K; Shiota Y; Ono T; Taniyama K; Hiramoto T; Yamakido M
Nihon Kokyuki Gakkai Zasshi; 2007 Feb; 45(2):153-9. PubMed ID: 17352172
[TBL] [Abstract][Full Text] [Related]
32. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.
Kao SC; Vardy J; Chatfield M; Corte P; Pavlakis N; Clarke C; van Zandwijk N; Clarke S
Clin Lung Cancer; 2013 Jan; 14(1):70-7. PubMed ID: 22658812
[TBL] [Abstract][Full Text] [Related]
33. Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.
Gaafar R; Bahnassy A; Abdelsalam I; Kamel MM; Helal A; Abdel-Hamid A; Eldin NA; Mokhtar N
Lung Cancer; 2010 Oct; 70(1):43-50. PubMed ID: 20347505
[TBL] [Abstract][Full Text] [Related]
34. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
35. Plasma platelet-derived growth factor: preliminary study of a potential marker in head and neck cancer.
Gleich LL; Srivastava L; Gluckman JL
Ann Otol Rhinol Laryngol; 1996 Sep; 105(9):710-2. PubMed ID: 8800057
[TBL] [Abstract][Full Text] [Related]
36. Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma?
Maeda R; Tabata C; Tabata R; Eguchi R; Fujimori Y; Nakano T
Antioxid Redox Signal; 2011 Aug; 15(3):685-9. PubMed ID: 21375472
[TBL] [Abstract][Full Text] [Related]
37. Malignant pleural mesothelioma: some aspects of epidemiology, differential diagnosis and prognosis. Histological and immunohistochemical evaluation and follow-up of mesotheliomas diagnosed from 1964 to January 1985.
Walz R; Koch HK
Pathol Res Pract; 1990 Feb; 186(1):124-34. PubMed ID: 1690413
[TBL] [Abstract][Full Text] [Related]
38. Coalescent pleural malignant mesothelioma and adenocarcinoma of the lung, involving only minor asbestos exposure.
Tsuzuki T; Ninomiya H; Natori Y; Ishikawa Y
Pathol Int; 2008 Jul; 58(7):451-5. PubMed ID: 18577116
[TBL] [Abstract][Full Text] [Related]
39. Platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and EGF and PDGF beta-receptors in human endometrial tissue: localization and in vitro action.
Chegini N; Rossi MJ; Masterson BJ
Endocrinology; 1992 Apr; 130(4):2373-85. PubMed ID: 1312455
[TBL] [Abstract][Full Text] [Related]
40. Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers.
Creaney J; Dick IM; Musk AW; Olsen NJ; Robinson BW
Biomarkers; 2016 Sep; 21(6):551-61. PubMed ID: 27009350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
